Cancer

Disclaimer:  While every attempt is made to ensure that drug dosages provided within the text of this journal and the website are accurate, readers are urged to check drug package inserts before prescribing. Views and opinions in this publication and the website are not necessarily endorsed by or reflective of those of the publisher.

Management of Cancer Pain in the Older Adult

Sharon Watanabe, MD, FRCPC and Yoko Tarumi, MD, Tertiary Palliative Care Unit, Regional Palliative Care Program, Edmonton, AB.

Cancer pain is a significant problem in older adults. Management in this population is made more challenging by issues such as comorbid conditions and age-related alterations in drug disposition. The first step is to perform a multidimensional assessment in order to identify the various factors that may influence the perception and expression of pain. The second step is to apply a process of targeted interventions, which optimizes the use of pharmacological and non-pharmacological therapies and takes into consideration the unique characteristics of the older patient.
Key words: cancer pain, pain assessment, opioids, adjuvant analgesics.

An Approach to the Solitary Lung Nodule in Older Adults

Cherdchai Nopmaneejumruslers, MD, Senior Clinical and Research Fellow, Division of Respirology, University of Toronto, Toronto, ON.
Charles K.N. Chan, MD, FRCPC, FCCP, FACP, Head, Division of Respirology, University Health Network, Mount Sinai Hospital, Sunnybrook & Women's College Health Sciences Centre, University of Toronto, Toronto, ON.

A diagnostic dilemma of a solitary pulmonary nodule (SPN) is a common clinical problem in the older population. Most pulmonary nodules are discovered incidentally on chest radiographs. Signs and symptoms are rarely present until the disease has become advanced and unresectable. Therefore, a timely and accurate diagnosis of the etiology of an SPN in early stage is essential to provide an excellent prognosis following surgical resection. Based on the best evidence, the algorithm presented in this article was made to provide the clinician with a clinical management pathway of the solitary lung nodule in older adults.
Key words: solitary pulmonary nodule, lung cancer, PET scan, diagnostic workup, VATS.

Diagnosis and Management of Renal Cell Carcinoma

Christina M. Canil, MD, FRCPC, Clinical Research Fellow and Jennifer J. Knox, MD, MSc, FRCPC, Staff Medical Oncologist; Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON.

Renal cell carcinoma is more prevalent in older people. The incidence of this cancer is rising secondary to incidental detection on routine imaging. In localized disease, radical nephrectomy is standard therapy; however, options of laparoscopic procedures or surveillance may be appropriate for small tumours. Treatment of advanced or metastatic renal cell carcinoma is limited and the main goal of therapy is palliation of symptoms. Nephrectomy and surgical removal of metastases have been shown to improve survival in patients with good performance status. Results with chemotherapy have been disappointing, but clinical trials of novel systemic agents are underway.
Key words: renal cell carcinoma, kidney cancer, older person, nephrectomy, interferon.

Primary Brain Tumours in the Elderly

Tara Morrison, MD and James R. Perry, MD, Crolla Family Brain Tumour Research Unit, Division of Neurology, Sunnybrook and Women's College Health Sciences Centre; University of Toronto, Toronto, ON.

Primary brain tumours are most commonly diagnosed in elderly individuals and the incidence of these uniformly fatal malignancies is on the rise. Recent studies have shown that the most common of these tumours, the glioblastoma multiforme, is genetically different in elderly compared to younger patients. Current research studies exploiting the genetic differences of these tumours as anti-cancer targets hold promise for the immediate future. At present the focus of brain tumour treatment is excellent supportive care. Radiation treatment and chemotherapy are being actively revisited to maximize quality of life. In addition, complications such as venous thromboembolism, seizures and therapy-induced adverse effects have received much attention and are reviewed in this article.
Key words: brain neoplasms, glioblastoma multiforme, palliative care, chemotherapy.

Prostate Cancer: Principles and Practice

Editors: Kantoff P.W., Carroll P.R., D'Amico A.V.
Lippincott Williams & Wilkins, 2001.

Reviewed by: Shabbir M.H. Alibhai, MD, MSc, FRCP(C), Senior Editor, Geriatrics & Aging.

Prostate cancer has been enjoying significant attention in the media over the past few years. Famous individuals such as Health Minister Allan Rock and General Schwartzkopf have been diagnosed and treated in recent years. Much information has been published, in an increasingly compartmentalised and specialised fashion, on the subject in the past decade. This textbook's purpose is to bring together the data from basic science and clinical disciplines in a comprehensive examination of prostate cancer. I should mention at the outset that I have significant research interests in this field, particularly from the geriatric angle, so my perspective on this book may be a little slanted.

To begin with, this reference is written by a host of distinguished American genitourinary oncologists. With very few exceptions, the list of contributors includes the major researchers in the field. Unfortunately, of approximately 100 authors, only two are not American. Thus, a wealth of international (and Canadian) experience in prostate cancer is ignored, and a primarily American perspective on this disease is presented. While this may not be an issue in some fields, in prostate cancer there are significant international differences in thinking with respect to screening, diagnosis and treatment.

The book is organised into eight sections, covering biology, epidemiology, diagnosis, early prostate cancer treatment (two sections), advanced disease (two sections) and future directions. Chapters are generally organised logically, and text and tables are nicely formatted and easy to read. Some chapters have many tables and figures to help facilitate knowledge transfer, whereas others are monotonous and almost exclusively text-based.

The section on biology has some very useful material on anatomy, cellular and molecular biology, genetics and cancer prevention. The anatomy chapter would have been aided by a few diagrams illustrating the anatomy of the prostate in relation to surrounding structures; pity the authors presumed the readers would not find this information useful.

The section on epidemiology is quite interesting. An excellent review of nutritional factors by a world authority includes pertinent sections on vitamins D and E, lycopenes, soy and selenium. However, there is no mention of the ongoing, large SELECT (selenium and vitamin E) randomised prevention trial sponsored by the National Cancer Institute. Peter Albertsen's chapter on age, comorbidity and prostate cancer is particularly relevant to geriatricians and clinical epidemiology-types, such as myself.

Sections 4 and 5, covering single modality and multimodality treatment of localised disease, will be of particular interest to primary care clinicians. There are some useful chapters discussing the role of surgery, external-beam radiotherapy, brachytherapy and combined therapies. One chapter is dedicated to treatment complications such as incontinence and sexual dysfunction, although neither this chapter nor previous ones adequately discuss the risks of treatment complications by modality and patient characteristics. There is also very little discussion of the prevalence of pre-existing incontinence and erectile dysfunction in older adults. This is unfortunate, because both conditions impact upon treatment selection in practice. Moreover, the discussions around treatment do not, in my mind, distinguish the results achieved in specialised tertiary care centres from the average community setting. I found the material on adjuvant hormonal therapy somewhat sparse, given the number of studies published in this area in recent years. I also found the chapter on quality of life long on the theory of quality of life and how to measure it, and short on the actual quality of life after various treatments and complications. This is unfortunate, given the limited evidence in favour of treatment, particularly in older adults, and the major adverse effects of treatment. This is not adequately highlighted.

Chapters in remaining sections cover other interesting areas, including various complications of prostate cancer (hematologic, orthopedic, neurologic), psychosocial issues and a very comprehensive review of pain and symptom management (something with which many clinicians are not very proficient). From an evidence-based medicine perspective, the offerings vary. Some chapters are very careful to discuss the quality and quantity of evidence, whereas others (particularly the chapters on treatment of localised disease) are more cavalier and present the perspectives of expert clinicians with secondary use of studies to justify their positions. Overall, I was disappointed in the offerings, and there was scant mention of several important completed or ongoing clinical trials of management (e.g., the now-published Scandinavian trial of radical prostatectomy vs. watchful waiting and the ongoing PIVOT trial of surgery vs. watchful waiting).

In summary, this textbook will probably be useful to genitourinary specialists (clinicians and researchers) who want quick overviews of specific topics to inform or facilitate more detailed inquiries. Family physicians and general internists should be able to answer most of their questions equally well with a good urology or oncology textbook or a few good review articles on the subject. A stronger focus on methodology (one very good chapter on clinical trials notwithstanding) and evidence-based recommendations would have been an asset. A chapter on informing and empowering patient decision-making also would have been useful, as would a list of Internet-based resources for clinicians and patients. For the generalist, borrowing a copy from your local medical library and waiting for an improved second edition is probably your best bet.

Ocular Malignancies in the Elderly

E. Rand Simpson, MD, Associate Professor of Ophthalmology, University of Toronto; Director, Ocular Oncology, Princess Margaret Hospital, Toronto, ON.
Larry Ulanski II, MD, Ocular Oncology Fellow, University of Toronto, Princess Margaret Hospital, Toronto, ON.

Ocular malignancies in the elderly are often difficult to diagnose and manage. The five main cancers found in association with the eye are basal, squamous and sebaceous cell carcinomas, uveal melanoma and malignant cancers to the orbit. These include malignancies from breast, lung, GI, prostate and myelogenous proliferations. This article briefly reviews the most common forms of ocular cancer and brings the general practitioner up to date on the most current data from the Collaborative Ocular Melanoma Study (COMS). We use clinical photos to demonstrate specific clinical signs of cancerous disease. By maintaining a high level of suspicion when treating patients with acute visual symptoms, unnecessary morbidity and mortality may be avoided.
Key words: ophthalmology, cancer, radiotherapy, malignancy.

Management of Hot Flashes in Men with Prostate Cancer

Dr. Neil Baum, MD, Urologist and Clinical Associate Professor of Urology, Tulane Medical School, New Orleans, LA, USA.
Dorothea Torti, Stanford University, CA, USA.

Prostate cancer is the most common cancer in men in North America. One of the treatment options is medical castration using LHRH agonists to reduce the production of testosterone by the Leydig cells in the testes. One of the side effects of this class of agents is hot flashes, which can be very disabling and can affect a man's quality of life. This article will discuss the pathophysiology of hot flashes and the treatment of this common side effect with natural and synthetic female hormones, as well as non-hormonal therapies.
Key words: prostate cancer, hot flashes, LHRH agonists, hormone therapy.

Lung Cancer Screening and Management in the Elderly Patient

Yaron Shargall, MD and Michael R. Johnston, MD, FRCSC, Division of Thoracic Surgery, Department of Surgery, University of Toronto; Division of Thoracic Surgery and Department of Surgical Oncology, Toronto General and Princess Margaret Hospitals, Toronto, ON.

Introduction
Lung cancer is the leading cause of cancer death in Canada and the Western world. In the year 2001, it is estimated that 21,200 people in Canada will be diagnosed with lung cancer, and approximately 18,500 people will die as a result.1 Despite extensive research and clinical efforts, the survival rate has not changed appreciably over the past 30 years and remains poor, with an overall five-year survival of about 13%.2 Lung cancer is predominantly a disease of the elderly, since more than 60% of all lung cancer cases occur in people older than 60 years.3 There is overwhelming experimental and epidemiological data to support the contention that cigarette smoking is the primary risk factor for the development of lung cancer. Of all lung cancers in Canada, 85% are directly attributable to smoking, and another 3% may be caused by second-hand smoking.4 In this article, we summarize the current status of lung cancer screening and treatment, with special emphasis on the elderly population.

Screening for Lung Cancer
Lung cancer screening studies have not clearly demonstrated a reduction in mortality.

Feedback from Our Readers

Feedback from Our Readers

In the July/August 2002 issue of Geriatrics & Aging (Volume 5, Number 6), the article "Dietary Measures to Prevent Prostate Cancer" (pages 18-20) suggested that dairy foods are strongly linked to prostate cancer, and that the higher the intake of dairy foods, the higher the risk of cancer. Mr. Thomas Anderson, PhD from Summerland, B.C., wrote G&A to point out that only defatted dairy products are known to have this effect (e.g., skim milk and fat-free yogurt), whereas unaltered dairy foods do not, and in fact appear to actually protect against prostate, breast and several other types of cancer. References provided by Mr. Anderson include:

  1. Ip C, Scimeca JA, Thompson HJ. Conjugated linoleic acid: powerful anticarcinogen from animal fat sources. Cancer 1994;74:1050-4.
  2. Jonnalagadda SS, Mustad VA, Yu S, et al. Effects of individual fatty acids on chronic diseases. Nutrition Today 1996;31:90-106.
  3. Knekt P, Jarvinen R, Seppanen R, et al. Intake of dairy products and the risk of breast cancer. British Journal of Cancer 1996;73:687-91.
  4. Veierod MB, Leake P, Thelle DS. Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. Int J Cancer 1997;73:634-8.
  5. Schuuman AG, Van den Brandt PA, Dorrant E, et al. Animal products, calcium and protein and prostate cancer in the Netherlands Cohort Study. Br J Cancer 1999;80:1107-13.

We thank Mr. Anderson for his feedback and encourage our readers to send their comments.

Geriatrics & Aging, 20 Eglinton Ave. West, Suite 1109, Toronto, ON M4R 1K8 Fax: 416-480-2740 or Email: info@geriatricsandaging.ca.

A Review of Smoking in the Elderly

D'Arcy Little, MD, CCFP, Lecturer and Academic Fellow, Department of Family and Community Medicine, University of Toronto; Director of Medical Education, York Community Services; 2002 Royal Canadian Legion Fellow in Care of Elderly at Baycrest Centre, Toronto, ON.

Prevalence of Smoking in the Elderly
Smoking is one of the major causes of morbidity and mortality in Canada. In fact, it has been called the leading preventable cause of death in North America.1 This is because smoking is a known risk factor for four of the leading causes of death in the industrialized world--coronary heart disease, cancer, lung disease and stroke--and because it contributes to many other causes of morbidity.2 While the current prevalence of smoking in Canadians aged 15 years and older declined by 10.3% between 1985 and 1999, the numbers remain high for both men and women (26.8% and 22.9%, respectively, in 1999).3 In those aged 65 and older, current smoking prevalence decreased by 8.9% over the same time period. However, it is estimated that 11.6% of seniors continue to smoke. The prevalence of smoking is highest in the Atlantic provinces and Quebec, and lowest in Saskatchewan and Ontario.4

Impact of Smoking on Health of the Elderly

Mortality
The health-related impact of smoking in the elderly is manifold. The increase in mortality has already been mentioned.